Literature DB >> 19132205

The technique of measuring thrombin generation with fluorescent substrates: 4. The H-transform, a mathematical procedure to obtain thrombin concentrations without external calibration.

H Coen Hemker1, Pieter W Hemker, Raed Al Dieri.   

Abstract

In fluorogenic thrombin generation (TG) experiments, thrombin concentrations cannot be easily calculated from the rate of the fluorescent signal increase, because the calibration coefficient increases during the experiment, due to substrate consumption and quenching of the fluorescent signal by the product. Continuous, external calibration via an in a parallel sample therefore was hitherto required for an accurate calculation of the TG curve. A technique is presented that allows mathematical transformation of experimental fluorescence intensities into "ideal" data, i.e. in the data that would have been obtained if substrate consumption and quenching by the product would not play a role. The method applies to fluorescence intensities up to 90% of the maximal fluorescent signal corresponding to total substrate conversion and thereby covers the entire region of interest encountered in practice. The first derivative of the transformed signal can then be converted into thrombin concentrations via a conventional, fixed calibration factor. This calibration factor can be obtained from a separate experiment but also by measuring the amidolytic activity of the alpha(2)macroglobulin-thrombin complex present in the reaction mixture ("serum") after thrombin generation is over. This method halves the amount of sample required per experiment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19132205

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Patients With Multiple Myeloma Have a Disbalanced Whole Blood Thrombin Generation Profile.

Authors:  Li Li; Mark Roest; Yaqiu Sang; Jasper A Remijn; Rob Fijnheer; Karel Smit; Dana Huskens; Jun Wan; Bas de Laat; Joke Konings
Journal:  Front Cardiovasc Med       Date:  2022-06-27

2.  Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation.

Authors:  Saartje Bloemen; H Coenraad Hemker; Raed Al Dieri
Journal:  Haematologica       Date:  2012-10-25       Impact factor: 9.941

3.  Interconnectedness of global hemostasis assay parameters in simultaneously evaluated thrombin generation, fibrin generation and clot lysis in normal plasma.

Authors:  Kevin Z Xin; William C Chang; Mikhail V Ovanesov
Journal:  Thromb Res       Date:  2015-11-19       Impact factor: 3.944

4.  A novel, rapid method to compare the therapeutic windows of oral anticoagulants using the Hill coefficient.

Authors:  Jeremy B Chang; Kayla M Quinnies; Ronald Realubit; Charles Karan; Jacob H Rand; Nicholas P Tatonetti
Journal:  Sci Rep       Date:  2016-07-21       Impact factor: 4.379

5.  Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing.

Authors:  Saartje Bloemen; Suzanne Zwaveling; Hugo Ten Cate; Arina Ten Cate-Hoek; Bas de Laat
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

6.  A novel assay for studying the involvement of blood cells in whole blood thrombin generation.

Authors:  Jun Wan; Joke Konings; Qiuting Yan; Hilde Kelchtermans; Romy Kremers; Bas de Laat; Mark Roest
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

7.  Thrombin Generation as a Method to Identify the Risk of Bleeding in High Clinical-Risk Patients Using Dual Antiplatelet Therapy.

Authors:  C P D M de Breet; S Zwaveling; M J A Vries; R G van Oerle; Y M C Henskens; A W J Van't Hof; P E J van der Meijden; L Veenstra; H Ten Cate; R H Olie
Journal:  Front Cardiovasc Med       Date:  2021-06-10

8.  The effects of oral contraceptive usage on thrombin generation and activated protein C resistance in Saudi women, with a possible impact of the body mass index.

Authors:  Abdulrahman B O Mohamed; Hilde Kelchtermans; Joke Konings; Jamilla van Daal; Anas Al Marzouki; Steve Harakeh; Bas de Laat
Journal:  PLoS One       Date:  2018-10-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.